The pharmacotherapy management of patients with heart failure with reduced ejection fraction is a populated landscape with multiple drugs affecting morbidity and mortality. Two new medications that are the first in two new classes were approved recently - a neprilysin inhibitor and a hyperpolarization-activated cyclic nucleotide-gated channel blocker.
But first here's a quick table and a few notes about the current use of medications for treating heart failure with reduced ejection fraction.
HughesMedicine - Pharmacotherapy Pearls from the Internal Medicine Clinical Pharmacist
Recommended for you
-
Let’s start with a patient case. A patient is being treated with methylprednisolone 20 mg IV q6 hours for some inflammatory process and...
-
The American Geriatrics Society recently published their Alternative Treatments to Selected Medications in reference to the most recent upd...
-
Since it's the time of year again when Lyme disease is a concern for patients in many parts of the United States, I thought it would b...
-
Thrombocytopenia is a notable adverse effect of linezolid. Some of the evidence behind the onset, duration, and the extent of platelet de...
-
A 48 year old male is admitted to the hospital after experiencing a fever and malaise for several days. He states that he has some shortn...
-
A 55 year old business executive is being discharged from the hospital after a brief admission for cellulitis. His only PMH is HTN and o...
-
Let’s start with a patient scenario. A patient presents to the emergency room experiencing a heart failure exacerbation. When entering th...
-
The management of anticoagulant therapy is an important component of the treatment of various disease states. Maintaining the narrow ther...
-
Let’s start with a patient case. Patient is an 80 year old female hospitalized for pneumonia with sepsis who during this admission expe...
-
Let’s start with a patient case. A patient is admitted to the hospital with a CHF exacerbation. They are taking warfarin for atrial fi...
